Übersicht – Systemtherapie des fortgeschrittenen metastasierten Melanoms

Melanome gehen aus den Melanozyten der Haut, selten auch der Schleimhäute, Uvea oder der Meningen hervor und gehören zu den aggressivsten Tumoren mit drastisch steigender Inzidenz und hoher Therapieresistenz [1]. Die Prognose der Erkrankung richtet sich im Wesentlichen nach der TNM-Klassifikation und dem daraus resultierenden Stadium des American Joint Committee on Cancer (AJCC) 2009, wobei die Chance für eine kurative Therapie in den frühen Tumorstadien am größten ist [2]. Durch neue Therapieansätze haben sich die Überlebensraten sowie die Anzahl der Patienten mit langfristiger Tumorkontrolle beim fernmetastasierten Melanom in den vergangenen Jahren erfreulicherweise deutlich erhöht.

• Literatur

• 1 Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014; 346: 945-949
• 2 Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206
• 3 Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 2004; 40: 1825-1836
• 4 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
• 5 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
• 6 Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
• 7 Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39
• 8 Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714
• 9 Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451
• 10 Van Allen EM, Wagle N, Sucker A et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4: 94-109
• 11 Larkin J, Ascierto PA, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
• 12 Dummer R, Schadendorf D, Ascierto P et al. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol 2016; 34
• 13 Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909
• 14 Hodi FS, Corless CL, Giobbie-Hurder A et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31: 3182-3190
• 15 Novartis NCT01028222: A Study of AMNN107 in the Treatment of Metastatic and / or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM). Clinical trialsgov 2015
• 16 Hodi FS, OʼDay SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
• 17 Lebbe C, Weber JS, Maio M et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014; 25: 2277-2284
• 18 Dick J, Enk A, Hassel JC. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?. Dermatology 2015; 230: 8-10
• 19 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
• 20 Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030
• 21 Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521-2532
• 22 Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117
• 23 Weber JS, DʼAngelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384
• 24 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
• 25 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34
• 26 Wolchok JD, Hoos A, OʼDay S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420
• 27 Reule RB, North JP. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 2013; 69: e272-273
• 28 Hassel JC, Lee SB, Meiss F et al. Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncoimmunology 2016; 5: e1101207
• 29 Hu-Lieskovan S, Robert L, Homet Moreno B et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014; 32: 2248-2254
• 30 Ribas A, Hodi FS, Callahan M et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-1366
• 31 Andtbacka RH, Ross M, Puzanov I et al. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol 2016;
• 32 Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534: 396-401
• 33 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557
• 34 Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22 952–26001 study. J Clin Oncol 2011; 29: 134-141
• 35 Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465
• 36 Rauschenberg R, Tabatabai G, Troost EG et al. [Melanoma brain metastases : Treatment options]. Hautarzt 2016; 67: 536-543
• 37 Ajithkumar T, Parkinson C, Fife K et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol 2015; 16: e486-497
• 38 Hecht M, Zimmer L, Loquai C et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 2015; 26: 1238-1244
• 39 Lang N, Sterzing F, Enk AH et al. Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlenther Onkol 2014; 190: 1080-1081